Two presentations on the results of the KEYNOTE-427 clinical trial were given at the American Society of Clinical Oncology (ASCO) 2019 annual meeting in Chicago this week. KEYNOTE-427 is an open-label, multicentre, global phase 2 study evaluating the efficacy and safety of pembrolizumab as a first-line treatment for patients with advanced or metastatic renal cell carcinoma (RCC). The study was divided into patients with clear cell RCC and patients with non-clear cell RCC, and these patient groups were presented separately at ASCO 2019.
For patients with non-clear cell RCC, first-line pembrolizumab continued to show promising anti-tumour activity after more than one year of follow-up. The overall response rate for all non-clear cell RCC patients was 21.6%, for papillary RCC it was 28%, for unclassified RCC it was 30.8%, and for chromophobe RCC it was 9.5%. The median duration of response was 15.3 months, and more than half the patients had a response lasting more than 12 months.
In both groups of patients (clear cell and non-clear cell RCC), the safety profile was as expected based on previous studies with pembrolizumab. These results support further evaluation of pembrolizumab in patients with advanced clear cell and non-clear cell RCC.